Skip to content

Capabilities
Locations
News
Careers
Participate
- Join a clinical trial
- Únase a un ensayo clínico
Contact

What We Do
About Velocity
- Overview
- Leadership
- Locations
- News
- Videos
- Case Studies
- Events
- #VelocityCares
- Contact
Join Us

Brandon Essink, MD, CPI, is Co-Principal Investigator for Moderna’s Phase 3 COVID-19 Vaccine Clinical Trial

July 27, 2020

Brandon Essink, MD, CPI, is a co-principal investigator for the Phase 3 clinical trial of Moderna’s COVID-19 vaccine. Read the full National Institutes of Health (NIH) press release: https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins

Posted in News

Posts navigation

← Paul Bradley, MD, Enrolls First Participant in Moderna’s Phase 3 COVID-19 Vaccine Clinical Trial

Meridian (Now Velocity Clinical Research) Wins 2020 Vaccine Industry Excellence (ViE) Awards for Best Clinical Trial Site and Best Clinical Trial Network →

Brandon Essink, MD, CPI, Co-Authors Article Published in the Journal, Vaccine

Recent posts

Henrik Watz, MD, PhD, Presents Promising Asthma Trial Results at ATS 2025 May 22, 2025
Beyond the U.S.: How Velocity is Redefining Clinical Trials Internationally May 15, 2025
Velocity Sites Help Deliver Promising Results in NEJM: Once-Weekly Semaglutide Shows Positive Affect on MASH, Liver Fibrosis May 9, 2025
Brandon Essink, MD, CPI, Publishes Article for ACRP and Clinical Trials Day May 8, 2025
Paul Evans Featured in Applied Clinical Trials Article on Impact of Executive Orders on DEI Initiatives April 15, 2025

Quality. Continuity. Velocity.

Contact Velocity

Velocity Clinical Research is the world’s leading organization of fully integrated research sites. The company partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, and diagnostics that could improve human health and wellbeing. Velocity's unified research site solutions deliver the right patients, investigators, and research staff for clinical trials across the U.S. and Europe.

LinkedIn
X
Instagram
Facebook

Join a Study
Browse Velocity Locations
Capabilities
Careers
Contact
US Cookie Policy
EU Cookie Policy
UK Cookie Policy
Imprint
Disclaimer

©2025 Velocity Clinical Research | All Rights Reserved | Privacy Policy | Terms of Use

What We Do
About Velocity
- Overview
- Leadership
- News
- Insights
- Events
- #VelocityCares
Join Us
Contact

Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions. Cookie Policy (US) Cookie Policy (EU) Cookie Policy (UK)

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage {vendor_count} vendors Read more about these purposes

View preferences

{title} {title} {title}